Status:
COMPLETED
An Open, Prospective, Randomized, Multicenter Study of the Efficacy and Safety of Intravenous Followed by Oral Azithromycin Versus Cefuroxime Alone or With Oral Erythromycin for the Treatment of Chinese Patients Who Were Hospitalized for Pneumonia
Lead Sponsor:
Pfizer
Conditions:
Pneumonia
Eligibility:
All Genders
18-70 years
Phase:
PHASE3
Brief Summary
To validate the efficacy and safety of azithromycin for the treatment of Chinese patients hospitalized with community-acquired pneumonia (CAP), compared with cefuroxime or the combination of cefuroxim...
Eligibility Criteria
Inclusion
- Patients hospitalized with a diagnosis of community acquired pneumonia (CAP) as defined by the presence of new infiltrate(s) including manifestation of consolidation, patchy, diffuse or interstitial inflammation on chest X-ray with or without pleural effusion plus at least 1 of the following: new cough and expectoration or progression of respiratory symptoms with purulent sputum with or without chest pain; fever; auscultatory findings such as rales or evidence of pulmonary consolidation; blood leukocyte count \>10×109/L or \<4×109/L with or without \>15% bands or a blood leukocyte count between 4 and 10 with neutropils greater than or equal to 75%
Exclusion
Key Trial Info
Start Date :
January 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2003
Estimated Enrollment :
139 Patients enrolled
Trial Details
Trial ID
NCT00648726
Start Date
January 1 2003
End Date
August 1 2003
Last Update
April 1 2008
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Beijing, China, 100853
2
Pfizer Investigational Site
Shanghai, China, 200003
3
Pfizer Investigational Site
Shanghai, China, 200025
4
Pfizer Investigational Site
Shanghai, China, 200040